
    
      This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial
      to evaluate the efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in
      Patients with Hypertension and Dyslipidemia
    
  